Si Yuan Chew
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Si Yuan Chew has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Mariko Siyue Koh
Singapore General Hospital
3 shared publications Pei Yee Tiew
Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore, Singapore
2 shared publicationsAdrian Kok Wai Chan
Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore
1 shared publication- Amit Kansal
Department of Intensive Care Medicine, Ng Teng Fong General Hospital, National University Health System, Singapore, Singapore
1 shared publication Bernard Wee
Department of Radiology, Ng Teng Fong General Hospital, NUHS, Singapore
1 shared publicationButta Aman
Medical Affairs, Research, AstraZeneca Singapore, Singapore
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-15
The Disproportionate Burden of Cardiovascular Disease in Mild-to-Moderate COPD
Background: Cardiovascular disease (CVD) is a major comorbidity in chronic obstructive pulmonary disease (COPD). However, whether cardiovascular burden increases with the severity of COPD requires more nuanced investigation. This study investigated the association between COPD severity and CVD prevalence, and evaluated their independent and joint effects on long-term survival. Methods: This multicenter cohort study included 553 stable COPD patients. Disease severity was stratified by GOLD grades and the multidimensional BODEx index. Logistic regression and Cox proportional hazards models were used to evaluate CVD prevalence across severity stages and identify predictors of all-cause mortality. Results: Patients were classified as mild-to-moderate (GOLD 1– 2; 57.7%) or severe-to-very severe (GOLD 3– 4; 42.3%). A clear paradox emerged: CVD prevalence was significantly lower in severe-to-very severe COPD compared to mild-to-moderate disease (45.7% vs. 59.6%, P=0.001). Adjusted analysis indicated that severe airflow limitation was independently associated with lower odds of CVD (OR 0.68, P=0.038). Notably, CVD was a significant mortality predictor only in early-stage disease. Conversely, in advanced COPD, the multidimensional BODEx score > 4 emerged as the strongest independent predictor of mortality (HR 2.19, P< 0.001), rendering CVD history statistically non-significant (P=0.10). Conclusion: CVD burden is highest in mild-to-moderate stages, where it significantly drives mortality. In advanced disease, overall multidimensional severity (BODEx index) supersedes CVD to determine survival. These findings emphasize prioritizing early cardiovascular screening in mild COPD while utilizing multidimensional indices for advanced prognosis.
- 1 June 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-15
Open AccessThe Disproportionate Burden of Cardiovascular Disease in Mild-to-Moderate COPD
Background: Cardiovascular disease (CVD) is a major comorbidity in chronic obstructive pulmonary disease (COPD). However, whether cardiovascular burden increases with the severity of COPD requires more nuanced investigation. This study investigated the association between COPD severity and CVD prevalence, and evaluated their independent and joint effects on long-term survival. Methods: This multicenter cohort study included 553 stable COPD patients. Disease severity was stratified by GOLD grades and the multidimensional BODEx index. Logistic regression and Cox proportional hazards models were used to evaluate CVD prevalence across severity stages and identify predictors of all-cause mortality. Results: Patients were classified as mild-to-moderate (GOLD 1– 2; 57.7%) or severe-to-very severe (GOLD 3– 4; 42.3%). A clear paradox emerged: CVD prevalence was significantly lower in severe-to-very severe COPD compared to mild-to-moderate disease (45.7% vs. 59.6%, P=0.001). Adjusted analysis indicated that severe airflow limitation was independently associated with lower odds of CVD (OR 0.68, P=0.038). Notably, CVD was a significant mortality predictor only in early-stage disease. Conversely, in advanced COPD, the multidimensional BODEx score > 4 emerged as the strongest independent predictor of mortality (HR 2.19, P< 0.001), rendering CVD history statistically non-significant (P=0.10). Conclusion: CVD burden is highest in mild-to-moderate stages, where it significantly drives mortality. In advanced disease, overall multidimensional severity (BODEx index) supersedes CVD to determine survival. These findings emphasize prioritizing early cardiovascular screening in mild COPD while utilizing multidimensional indices for advanced prognosis.
- Open Access
- 1 July 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 2311-2324
Predictors of Clinical Stability and Mortality in COPD: A Longitudinal Study
Background: There is no consensus on the definition of clinical stability in chronic obstructive pulmonary disease (COPD), and it is less frequently used as a treatment target compared to severe asthma. The factors that determine clinical stability and their effects on mortality are less well-studied in patients with COPD. Methods: To address this gap, we conducted a prospective longitudinal cohort study to identify predictors of two-year clinical stability, defined as no exacerbations and stable symptoms (< 2 point change in CAT score from baseline), and the impact of comorbid cardiovascular disease (CVD) on clinical stability and mortality in COPD patients. Results: A total of 463 patients (mean age 71 ± 9 years) were enrolled in this study. The cohort was predominantly Chinese (81.7%) and 45.6% of participants were current smokers. The majority (55.7%) had a history of CVD. Approximately 36% of the cohort achieved clinical stability at one year, and one-third achieved stability at two years. Predictors of 2-year clinical stability included higher body mass index (BMI) (p< 0.001), higher post-bronchodilator FEV1/FVC ratio (p=0.0132), fewer baseline exacerbations (p=0.007), absence of bronchiectasis (p=0.045), preserved hemoglobin levels (p=0.019), and successful smoking cessation (p=0.039). Notably, while 2-year clinical stability did not predict subsequent mortality, the presence of CVD was a significant predictor of 5-years mortality (HR 1.48, 95% CI 0.99– 2.22; p=0.05). Conclusion: Our study identified several predictors of 2-year clinical stability in patients with COPD. However, clinical stability at 2 years did not predict subsequent mortality. These findings suggest that clinical stability and mortality are distinct outcomes that are driven by different sets of predictive variables. This underscores the need for a comprehensive approach to COPD management that not only addresses exacerbations and symptoms, but also considers a broader range of factors influencing survival, particularly the management of comorbidities such as cardiovascular disease.
- 1 July 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 2311-2324
Open AccessPredictors of Clinical Stability and Mortality in COPD: A Longitudinal Study
Background: There is no consensus on the definition of clinical stability in chronic obstructive pulmonary disease (COPD), and it is less frequently used as a treatment target compared to severe asthma. The factors that determine clinical stability and their effects on mortality are less well-studied in patients with COPD. Methods: To address this gap, we conducted a prospective longitudinal cohort study to identify predictors of two-year clinical stability, defined as no exacerbations and stable symptoms (< 2 point change in CAT score from baseline), and the impact of comorbid cardiovascular disease (CVD) on clinical stability and mortality in COPD patients. Results: A total of 463 patients (mean age 71 ± 9 years) were enrolled in this study. The cohort was predominantly Chinese (81.7%) and 45.6% of participants were current smokers. The majority (55.7%) had a history of CVD. Approximately 36% of the cohort achieved clinical stability at one year, and one-third achieved stability at two years. Predictors of 2-year clinical stability included higher body mass index (BMI) (p< 0.001), higher post-bronchodilator FEV1/FVC ratio (p=0.0132), fewer baseline exacerbations (p=0.007), absence of bronchiectasis (p=0.045), preserved hemoglobin levels (p=0.019), and successful smoking cessation (p=0.039). Notably, while 2-year clinical stability did not predict subsequent mortality, the presence of CVD was a significant predictor of 5-years mortality (HR 1.48, 95% CI 0.99– 2.22; p=0.05). Conclusion: Our study identified several predictors of 2-year clinical stability in patients with COPD. However, clinical stability at 2 years did not predict subsequent mortality. These findings suggest that clinical stability and mortality are distinct outcomes that are driven by different sets of predictive variables. This underscores the need for a comprehensive approach to COPD management that not only addresses exacerbations and symptoms, but also considers a broader range of factors influencing survival, particularly the management of comorbidities such as cardiovascular disease.
- 28 November 2024
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 53 (11) , 644-646
Can a Bayesian approach clarify if corticosteroids are beneficial for severe community-acquired pneumonia?
Despite advances in the antimicrobial treatment of sepsis and organ support in the intensive care unit (ICU), community-acquired pneumonia (CAP) remains a leading cause of mortality and disability-adjusted life years lost globally.1 Severe CAP, where CAP becomes complicated by acute hypoxaemic respiratory failure or shock, is also the most common cause of sepsis, where complex and heterogeneous biological mechanisms underlie a dysregulated inflammatory host response that ultimately leads to major organ dysfunction and death. Along with the emerging threats of respiratory pandemics, antimicrobial resistance, ageing populations and the rise of chronic diseases, much research has been conducted to improve the treatment outcomes of CAP via host immunomodulation. These efforts have focused almost exclusively on anti-inflammatory effects of corticosteroids, which have a proven track record of improving outcomes in other forms of sepsis, such as bacterial meningitis, Pneumocystis jirovecii pneumonia and severe COVID-19.
- 28 November 2024
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 53 (11) , 644-646
Can a Bayesian approach clarify if corticosteroids are beneficial for severe community-acquired pneumonia?
Despite advances in the antimicrobial treatment of sepsis and organ support in the intensive care unit (ICU), community-acquired pneumonia (CAP) remains a leading cause of mortality and disability-adjusted life years lost globally.1 Severe CAP, where CAP becomes complicated by acute hypoxaemic respiratory failure or shock, is also the most common cause of sepsis, where complex and heterogeneous biological mechanisms underlie a dysregulated inflammatory host response that ultimately leads to major organ dysfunction and death. Along with the emerging threats of respiratory pandemics, antimicrobial resistance, ageing populations and the rise of chronic diseases, much research has been conducted to improve the treatment outcomes of CAP via host immunomodulation. These efforts have focused almost exclusively on anti-inflammatory effects of corticosteroids, which have a proven track record of improving outcomes in other forms of sepsis, such as bacterial meningitis, Pneumocystis jirovecii pneumonia and severe COVID-19.
- 17 November 2023
- Published by BMJ in BMJ Case Reports
- Vol. 16 (11) , e257208
Pulmonary sclerosing pneumocytoma – approaching a solitary pulmonary nodule and the limitations of risk prediction models
Our case is an asymptomatic, non-smoking, East Asian woman in her 40s presenting with a solitary pulmonary nodule (SPN). On imaging, the 1.7 cm solid SPN located in the left upper lobe, was rounded in morphology and moderately fluorodeoxyglucose avid. The clinical pretest probability of malignancy assessed by risk prediction models such as Brock (19.1%), Mayo Clinic (56.2%) and Herder (51.4%) was discordant. She underwent a percutaneous CT-guided needle biopsy, establishing a diagnosis of pulmonary sclerosing pneumocytoma (PSP). PSP is a rare benign lung neoplasm with indolent growth characteristics that has been described predominantly in non-smoking women. Our case illustrates the limitations of applying existing risk prediction models in Asia where the epidemiology and biology of lung cancer differ significantly from the Caucasian derivation cohorts. Additionally, the risk models do not account for tuberculosis, which is endemic in Asia and can mimic malignancy. Non-surgical lung biopsy remains useful in minimising unnecessary thoracotomy.
- 17 November 2023
- Published by BMJ in BMJ Case Reports
- Vol. 16 (11) , e257208
Pulmonary sclerosing pneumocytoma – approaching a solitary pulmonary nodule and the limitations of risk prediction models
Our case is an asymptomatic, non-smoking, East Asian woman in her 40s presenting with a solitary pulmonary nodule (SPN). On imaging, the 1.7 cm solid SPN located in the left upper lobe, was rounded in morphology and moderately fluorodeoxyglucose avid. The clinical pretest probability of malignancy assessed by risk prediction models such as Brock (19.1%), Mayo Clinic (56.2%) and Herder (51.4%) was discordant. She underwent a percutaneous CT-guided needle biopsy, establishing a diagnosis of pulmonary sclerosing pneumocytoma (PSP). PSP is a rare benign lung neoplasm with indolent growth characteristics that has been described predominantly in non-smoking women. Our case illustrates the limitations of applying existing risk prediction models in Asia where the epidemiology and biology of lung cancer differ significantly from the Caucasian derivation cohorts. Additionally, the risk models do not account for tuberculosis, which is endemic in Asia and can mimic malignancy. Non-surgical lung biopsy remains useful in minimising unnecessary thoracotomy.
- 5 May 2021
- Published by SAGE Publications in Anaesthesia and Intensive Care
- Vol. 49 (3) , 240-241
Inferior vena cava filter migration due to guidewire ensnarement during peripherally inserted central catheterisation
- 5 May 2021
- Published by SAGE Publications in Anaesthesia and Intensive Care
- Vol. 49 (3) , 240-241
Inferior vena cava filter migration due to guidewire ensnarement during peripherally inserted central catheterisation
- Open Access
- 1 June 2020
- Published by BMJ in BMJ Open Quality
- Vol. 9 (2) , e000894
Improving asthma care with Asthma-COPD Afterhours Respiratory Nurse at Emergency (A-CARE)
Background Emergency departments (ED) are important providers of asthma care, particularly after-hours. We identified gaps for quality improvement such as suboptimal adherence rates to three key recommendations from the Global Initiative for Asthma (GINA) guidelines for discharge management asthma guidelines. These were: the prescription of oral and inhaled corticosteroids (OCS and ICS) and issuance of outpatient follow-up for patients discharged from the ED. Aim To achieve an adherence rate of 80% to GINA guidelines for ED discharge management by providing after-hours asthma counselling services. Methods We implemented Asthma-COPD Afterhours Respiratory Nurse at Emergency (A-CARE) according to the Plan-Do-Study-Act (PDSA) framework to provide after-hours asthma counselling and clinical decision support to ED physicians three nights a week. Data on adherence rates to the GINA guidelines were collected and analysed on a run chart. Results After 17 months’ follow-up, a sustained improvement was observed in patients reviewed by A-CARE in the median adherence rates to OCS prescription (58% vs 86%), ICS initiation (27% vs 67%) and issuance of follow-up (69% vs 92%), respectively. The overall impact was, however, limited by a suboptimal referral rate to A-CARE (16%) in a clinical audit of all ED patients with asthma. Nonetheless, in this audit, attendance rates for patients referred to our respiratory department for follow-up were higher in those receiving asthma counselling compared with those who did not (41.7% vs 15.9%, p=0.0388). Conclusion Sustained improvements in the adherence rates to guidelines were achieved for patients reviewed by A-CARE but were limited in overall impact due to suboptimal referral rate. We plan to improve the quality of asthma care by implementing further PDSA cycles to increase the referral rates to A-CARE.
- 1 June 2020
- Published by BMJ in BMJ Open Quality
- Vol. 9 (2) , e000894
Open AccessImproving asthma care with Asthma-COPD Afterhours Respiratory Nurse at Emergency (A-CARE)
Background Emergency departments (ED) are important providers of asthma care, particularly after-hours. We identified gaps for quality improvement such as suboptimal adherence rates to three key recommendations from the Global Initiative for Asthma (GINA) guidelines for discharge management asthma guidelines. These were: the prescription of oral and inhaled corticosteroids (OCS and ICS) and issuance of outpatient follow-up for patients discharged from the ED. Aim To achieve an adherence rate of 80% to GINA guidelines for ED discharge management by providing after-hours asthma counselling services. Methods We implemented Asthma-COPD Afterhours Respiratory Nurse at Emergency (A-CARE) according to the Plan-Do-Study-Act (PDSA) framework to provide after-hours asthma counselling and clinical decision support to ED physicians three nights a week. Data on adherence rates to the GINA guidelines were collected and analysed on a run chart. Results After 17 months’ follow-up, a sustained improvement was observed in patients reviewed by A-CARE in the median adherence rates to OCS prescription (58% vs 86%), ICS initiation (27% vs 67%) and issuance of follow-up (69% vs 92%), respectively. The overall impact was, however, limited by a suboptimal referral rate to A-CARE (16%) in a clinical audit of all ED patients with asthma. Nonetheless, in this audit, attendance rates for patients referred to our respiratory department for follow-up were higher in those receiving asthma counselling compared with those who did not (41.7% vs 15.9%, p=0.0388). Conclusion Sustained improvements in the adherence rates to guidelines were achieved for patients reviewed by A-CARE but were limited in overall impact due to suboptimal referral rate. We plan to improve the quality of asthma care by implementing further PDSA cycles to increase the referral rates to A-CARE.
- 15 August 2019
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 200 (4) , 507-509
Clinical Heterogeneity in Bronchiectasis. Recommended Reading from the Singapore Respiratory Medicine Fellows
- 15 August 2019
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 200 (4) , 507-509
Clinical Heterogeneity in Bronchiectasis. Recommended Reading from the Singapore Respiratory Medicine Fellows
- Open Access
- 25 June 2019
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 25 (2) , 218-222
VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature
- 25 June 2019
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 25 (2) , 218-222
Open AccessVIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature
- 15 December 2018
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 47 (12) , 523-527
Making Clinical Practice Guidelines Pragmatic: How Big Data and Real World Evidence Can Close the Gap
Clinical practice guidelines (CPGs) have become ubiquitous in every field of medicine today but there has been limited success in implementation and improvement in health outcomes. Guidelines are largely based on the results of traditional randomised controlled trials (RCTs) which adopt a highly selective process to maximise the intervention’s chance of demonstrating efficacy thus having high internal validity but lacking external validity. Therefore, guidelines based on these RCTs often suffer from a gap between trial efficacy and real world effectiveness and is one of the common reasons contributing to poor guideline adherence by physicians. “Real World Evidence” (RWE) can complement RCTs in CPG development. RWE—in the form of data from integrated electronic health records—represents the vast and varied collective experience of frontline doctors and patients. RWE has the potential to fill the gap in current guidelines by balancing information about whether a test or treatment works (efficacy) with data on how it works in real world practice (effectiveness). RWE can also advance the agenda of precision medicine in everyday practice by engaging frontline stakeholders in pragmatic biomarker studies. This will enable guideline developers to more precisely determine not only whether a clinical test or treatment is recommended, but for whom and when. Singapore is well positioned to ride the big data and RWE wave as we have the advantages of high digital interconnectivity, an integrated National Electronic Health Record (NEHR), and governmental support in the form of the Smart Nation initiative. Key words: Guideline adherence, Real world data, Physicians' practice patterns
- 15 December 2018
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 47 (12) , 523-527
Making Clinical Practice Guidelines Pragmatic: How Big Data and Real World Evidence Can Close the Gap
Clinical practice guidelines (CPGs) have become ubiquitous in every field of medicine today but there has been limited success in implementation and improvement in health outcomes. Guidelines are largely based on the results of traditional randomised controlled trials (RCTs) which adopt a highly selective process to maximise the intervention’s chance of demonstrating efficacy thus having high internal validity but lacking external validity. Therefore, guidelines based on these RCTs often suffer from a gap between trial efficacy and real world effectiveness and is one of the common reasons contributing to poor guideline adherence by physicians. “Real World Evidence” (RWE) can complement RCTs in CPG development. RWE—in the form of data from integrated electronic health records—represents the vast and varied collective experience of frontline doctors and patients. RWE has the potential to fill the gap in current guidelines by balancing information about whether a test or treatment works (efficacy) with data on how it works in real world practice (effectiveness). RWE can also advance the agenda of precision medicine in everyday practice by engaging frontline stakeholders in pragmatic biomarker studies. This will enable guideline developers to more precisely determine not only whether a clinical test or treatment is recommended, but for whom and when. Singapore is well positioned to ride the big data and RWE wave as we have the advantages of high digital interconnectivity, an integrated National Electronic Health Record (NEHR), and governmental support in the form of the Smart Nation initiative. Key words: Guideline adherence, Real world data, Physicians' practice patterns